Old blood pressure drug telmisartan could open broader cancer uses for PARP inhibitors
A Dartmouth Cancer Center study reports that the commonly used blood pressure drug telmisartan can enhance the anticancer effect of olaparib in preclinical models and bring immune responses into the fight; the real answer still awaits ongoing human trials.